2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
243
Neoplasms
17
Neoplasm Metastasis
15
Carcinoma, Intraductal, Noninfiltrating
11
Breast Diseases
8
Advanced Breast Cancer
8
Breast Neoplasms, Male
7
Breast Carcinoma In Situ
7
Triple Negative Breast Neoplasms
5
Ovarian Neoplasms
5
Endometrial Neoplasms
5
Arthralgia
5
Neoplasms by Site
3
Breast Cancer Metastatic
3
Uterine Cervical Neoplasms
2
Recurrence
2
Patient Compliance
2
Osteoporosis
2
Obesity
2
Multiple Endocrine Neoplasia Type 1
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasm Female
2
Vitamin D Deficiency
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Skin Diseases
1
Sexual Dysfunctions, Psychological
1
Sexual Dysfunction, Physiological
1
Seizures
1
Sarcoma
1
Interventions
Fulvestrant
10
Alpelisib
7
Everolimus
6
Cetuximab
6
Letrozole
4
serabelisib
3
ribociclib
3
pembrolizumab
3
palbociclib
3
duvelisib
3
berzosertib
3
Paclitaxel
3
PX-866
3
NVP-BKM120
3
Irinotecan
3
sapanisertib
2
parsaclisib
2
olaparib
2
binimetinib
2
Topotecan
2
Gemcitabine
2
Carboplatin
2
volagidemab
1
venetoclax
1
tivozanib
1
tipifarnib
1
tanezumab
1
talazoparib
1
sotorasib
1
ruxolitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
Anastrozole
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled